Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Interstitial Lung Disease Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The interstitial lung disease market has experienced robust expansion in recent times. Projections indicate a rise from $2.09 billion in 2025 to $2.24 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. This historical growth can be ascribed to several factors, including the increasing occurrence of chronic respiratory diseases, greater exposure to occupational and environmental pollutants, developments in pulmonary imaging techniques, heightened awareness of idiopathic pulmonary fibrosis, and the proliferation of specialty pulmonary clinics.
The market for interstitial lung disease is projected to experience substantial expansion in the coming years. By 2030, its size is anticipated to reach $3.09 billion, demonstrating a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period is primarily driven by factors such as an expanding aging population, an increase in the diagnosis rates of interstitial lung disorders, the broader adoption of targeted anti-fibrotic medications, an escalation of research into innovative ILD therapies, and enhanced patient screening and monitoring initiatives. Key trends expected over this period encompass a heightened focus on early and precise ILD diagnosis, the wider acceptance of anti-fibrotic treatments, a stronger emphasis on managing disease progression, the spread of multidisciplinary care strategies, and better availability of long-term ILD treatment options.
Get A Free Sample Report With In-Depth Market Insights:
Interstitial Lung Disease Market Growth Factors: What’s Supporting Expansion?
The interstitial lung disease market is anticipated to expand due to the increasing occurrence of autoimmune conditions. These ailments are defined as health issues where the body’s immune system mistakenly targets and damages its own healthy cells and tissues. The growing prevalence of autoimmune diseases influences the interstitial lung disease market by elevating the need for ILD-specific healthcare, stimulating research and development efforts, and fostering progress in treatment options and patient management. For example, data from September 2023, provided by the US-based global health research center, the Institute for Health Metrics and Evaluation, forecasts that global cases of rheumatoid arthritis will climb to an estimated 31.7 million by 2050, signifying a substantial increase during this timeframe. Consequently, the increased occurrence of autoimmune conditions is a key force propelling the expansion of the interstitial lung disease market.
Interstitial Lung Disease Market Segment Trends And Revenue Contributors
The interstitial lung disease market covered in this report is segmented –
1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs
2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis
3) By Application: Adults, Children
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil
3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib
4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies
Interstitial Lung Disease Market Industry Trends: What’s Reshaping Demand?
Major companies in the interstitial lung disease market are focusing on new product introductions, particularly innovative therapies for various interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring of lung tissue, which leads to breathing difficulties and reduced oxygen transfer. For example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a Germany-based biopharmaceutical company, received FDA approval for BI 1015550 Therapy for the treatment of Idiopathic Pulmonary Fibrosis. BI 1015550 is an investigational oral therapy that inhibits phosphodiesterase 4B (PDE4B), delivering antifibrotic and anti-inflammatory effects aimed at slowing lung function decline in idiopathic pulmonary fibrosis (IPF).
Interstitial Lung Disease Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceuticals USA Inc., AstraZeneca plc, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Insmed Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health plc, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc
View The Full Interstitial Lung Disease Market Report:
Interstitial Lung Disease Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the interstitial lung disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interstitial lung disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model








